Prognostic effects of the differences in histopathological evaluation between preoperative chemotherapy and preoperative chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma

Prognostic effects of the differences in histopathological evaluation between preoperative chemotherapy with Docetaxel, CDDP and 5-FU and preoperative chemoradiotherapy in locally advanced esophageal squamous cell carcinoma of Stage III or higher : a retrospective study in a single institution - Histopathological evaluation and treatment results of preoperative DCF and preoperative CRT for advanced esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045147

Enrollment

300

Registered

2021-10-01

Start date

2012-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with esophageal squamous cell carcinoma in the pretreatment pathological diagnosis. 2.Patients without simultaneous advanced another cancer. 3.Patients It is resistant to surgery in terms of general condition, cardiopulmonary function, and hepato-renal function. 4.Patients to be the candidates of chemotherapy / chemoradiotherapy 5.Patients with UICC7th cT3 or deeper but borderline excision ability , or cT3N1-3. 6.Patients undergoing radical surgery

Exclusion criteria

Exclusion criteria: 1. No pretreatment pathological diagnosis. 2. Simultaneous advanced another cancer. 3. Anxiety about surgical tolerance before treatment. 4. Chemotherapy cannot be performed due to organ function. 5. Although registered in each cohort before the start of preoperative treatment cases in which the actual surgery was not performed due to reasons including side effects of preoperative treatment, tumor regrowth during preoperative treatment and refusal of the patient.

Design outcomes

Primary

Measure	Time frame
To systematically examine the difference in histopathological evaluation between preoperative DCF and preoperative CRT and in the remote results of the cohorts	—

Secondary

Measure	Time frame
To clarify the central role of surgery in the multidisciplinary treatment by presenting the remote results of surgery alone performed without overlapping the patient registration period of preoperative chemotherapy and preoperative CRT cohorts.	—

Countries

Japan

Contacts

Public ContactMiyako Myojin

Keiyukai Sapporo Hospital Department of Radiation Oncology

miyako98kazm@gmail.com+81-11-863-2101

Outcome results